Close menu

May 17th, 2022 | 09:54 CEST

Alzheimer's share? Ask the CEO! Valneva, NervGen Pharma, Bayer

  • Biotech
  • Pharma
Photo credits:

High blood pressure, diabetes, stroke and Alzheimer's disease are scourges of our time. As people in industrialized countries grow older, it becomes increasingly likely that they will also suffer from one of these diseases. While there is likely to be a genetic predisposition for all of the ailments mentioned, lifestyle also plays a role. Lack of exercise and obesity often leads first to high blood pressure, then to diabetes, and ultimately to even worse conditions. In the event of a pandemic, all people with such pre-existing conditions belong to a high-risk group. Reason enough to take a closer look at stocks related to these issues and ask how investors can profit.

time to read: 4 minutes | Author: Nico Popp
ISIN: VALNEVA SE EO -_15 | FR0004056851 , NERVGEN PHARMA CORP | CA64082X2032 , BAYER AG NA O.N. | DE000BAY0017

Table of contents:

    Valneva: Trees do not grow to the sky

    The Corona pandemic is still ever-present. Those travelling abroad are still being checked: Vaccination status, body temperature, FFP2 mask. But around the world, people are tired of the pandemic. While masks are compulsory in official buildings, the situation is quite different in the countryside. People have lost their fear of the virus. That is probably one of the reasons why vaccination willingness is declining more and more. What was already bad news for latecomers, such as Valneva, compared to the top dogs from BioNTech and Moderna, is now becoming a disaster: Valneva has lost an advance purchase agreement for 60 million doses of the vaccine with the European Union. The EU has terminated the contract because approval has still not been received. Although the Company still has 30 days to make improvements and obtain approval, the signs are very bad.

    Yesterday, the share price plummeted by more than 20% at times. The fantasy surrounding the once celebrated "saviour of the skeptics" dead vaccine seems to have evaporated entirely. While the uptrend is not yet over from a long-term perspective, it does not currently look like the stock is strongly supported. If strong hands are missing in the coming days, the value will continue to fall.

    NervGen Pharma: Completely new approach to nerve damage

    The share of NervGen Pharma has developed in a somewhat volatile sideways direction in recent years. Recently, there were no significant swings in either direction. It is surprising because last week, the Company received a commitment to increase the dose in its Phase 1 trial of the active substance NVG-291. Phase 1 trials are all about drug safety. If the authorities give the green light for higher doses, that is a good sign. But what does NervGen actually do? The Company is dedicated to developing innovative treatments that enable the nervous system to repair itself, addressing some of the most significant diseases of our time: multiple sclerosis, Alzheimer's, stroke and spinal cord injury are devastating diagnoses. NervGen uses a discovery made by renowned scientist Dr Jerry Silver in the 1990s and translates it into a product.

    Simply put, when nerves are damaged, the body has the ability to heal them and restore their original function. However, due to scarring, this natural healing process ends after a time - patients remain restricted. Previous studies have shown that the active ingredient of NervGen could also have positive effects in humans on several levels: "The primary purpose of the scar is to protect the area from further damage. Unfortunately, the scar tissue contains a molecule that interacts with the nerves and ultimately halts natural healing. Our drug essentially modulates the activity of this molecule, allowing healing to occur naturally. One important way the nervous system heals itself is by increasing plasticity, i.e. growth of new nerve connections. Another process is called remyelination which is the rebuilding of the protective coating around the nerves, known as myelin. In studies of animals with stroke, we have even observed stem cells moving into the affected nerve areas, which also has the potential to contribute to healing," NervGen Executive Chairman Bill Radvak said in an interview.

    Alzheimer's, MS, paraplegia - NervGen CEO answers your questions!

    In the coming months, the Company plans to show that excellent results from animal experiments, in which mice with injured spinal cords were able to move their legs again, for example, can also be transferred to humans. It is important to note that even small results would be a scientific revolution - just restoring bladder function or minor improvements in MS, which also involves nerve injury, can ease the suffering of millions of people. Next Thursday, NervGen CEO Paul Brennan will present at the International Investment Forum (IIF) and then take questions from the audience. Attendance is free via Zoom, starting at 7:20 pm!

    Bayer: As boring as a boat trip on the Rhine

    Listening to the 30-minute keynote speech and asking a few questions afterwards could also be of interest to representatives of companies like Bayer. While the Company is currently scoring points with its seed business, pharmaceuticals still account for about 40% of total sales. Bayer offers an exciting mix of health care and food supply and should therefore be in demand in the current market environment. Recently, the stock has shown relative strength, but on a one-year horizon, it remains at a meager return of only 7.8%.

    To invest in health, investors can go several ways. Stocks such as Bayer are not very dynamic but offer a dividend - currently, the yield is around 3.6%. Valneva has been rated highly so far. These days, moreover, it could be all or nothing. For NervGen, the market has priced in some risks. However, the active ingredient, which potentially helps with various diseases and has the makings of a revolution, could be worth speculating on. Investors have enough time for a deep dive in the current market environment. This can be done without digging through technical literature or studies - on Thursday, exciting companies will be presenting at the IIF throughout the day, including NervGen from 7:20 pm onwards.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author

    Related comments:

    Commented by Fabian Lorenz on May 16th, 2024 | 08:00 CEST

    Share price shock at Siemens Energy! What are BioNTech and Cardiol Therapeutics doing?

    • Biotechnology
    • Pharma
    • renewableenergies

    The Siemens Energy share has been one of the surprises of recent months. It has more than doubled since the beginning of the year. Is a crash now imminent? Yes, if you believe Bernstein. Their analysts are shocking us with a horror price target. The Cardiol Therapeutics share performed even better than Siemens Energy in 2024. Despite the 150% rally, analysts see upside potential for the cardiovascular disease specialist. Things will get really exciting at the beginning of June when new study results are due. BioNTech, on the other hand, is currently failing to convince analysts. Reactions to the latest quarterly figures were modest.


    Commented by Stefan Feulner on May 14th, 2024 | 07:30 CEST

    Bayer, Defence Therapeutics, Novavax - Major events

    • Biotechnology
    • Pharma

    The biotechnology sector is still on the move and is currently characterized by a high degree of volatility. For instance, BioNTech, a former star during the pandemic, reported a net loss of EUR 315 million in the first quarter. The Mainz-based biotech now wants to focus more on the development of its cancer drugs due to the slump in demand for COVID-19 vaccines. However, for years, innovative, undiscovered companies have existed in this billion-dollar market that could, with their technologies, become the new high-flyers in the biotech industry.


    Commented by Fabian Lorenz on May 9th, 2024 | 08:00 CEST

    Stocks facing revaluation! Nel ASA, Bayer, Power Nickel with potential

    • Mining
    • Gold
    • Silver
    • Nickel
    • Pharma
    • renewableenergies

    Relief for Bayer. In the US, the Company has won a victory in the dispute over compensation for illnesses caused by the chemical PCB. Is it groundbreaking and the start of a revaluation of the share? A revaluation already seems to be underway at Power Nickel. Following sensational drilling results, the share price soared. Surprisingly, gold, silver and copper were also found. Against this backdrop, the share appears to be favorably valued. Does this also apply to Nel? After all, the share price has risen by around 20% in just a few weeks. Is there new hope for the hydrogen pioneer? Or are today's figures from industry peer Plug Power threatening a new sell-off?